ZA201103397B - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- ZA201103397B ZA201103397B ZA2011/03397A ZA201103397A ZA201103397B ZA 201103397 B ZA201103397 B ZA 201103397B ZA 2011/03397 A ZA2011/03397 A ZA 2011/03397A ZA 201103397 A ZA201103397 A ZA 201103397A ZA 201103397 B ZA201103397 B ZA 201103397B
- Authority
- ZA
- South Africa
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12059608P | 2008-12-08 | 2008-12-08 | |
| PCT/US2009/066941 WO2010068581A1 (en) | 2008-12-08 | 2009-12-07 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201103397B true ZA201103397B (en) | 2012-01-25 |
Family
ID=42243044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2011/03397A ZA201103397B (en) | 2008-12-08 | 2011-05-10 | Novel compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9163024B2 (enExample) |
| EP (1) | EP2370440B1 (enExample) |
| JP (1) | JP5666464B2 (enExample) |
| KR (1) | KR101743783B1 (enExample) |
| CN (1) | CN102245606B (enExample) |
| AU (1) | AU2009324811B2 (enExample) |
| BR (1) | BRPI0922134A2 (enExample) |
| CA (1) | CA2746316C (enExample) |
| CY (1) | CY1116032T1 (enExample) |
| DK (1) | DK2370440T3 (enExample) |
| EA (1) | EA020037B1 (enExample) |
| ES (1) | ES2527354T3 (enExample) |
| HR (1) | HRP20150026T1 (enExample) |
| IL (1) | IL213032A (enExample) |
| MX (1) | MX2011006022A (enExample) |
| PL (1) | PL2370440T3 (enExample) |
| PT (1) | PT2370440E (enExample) |
| RS (1) | RS53777B1 (enExample) |
| SI (1) | SI2370440T1 (enExample) |
| SM (1) | SMT201500012B (enExample) |
| WO (1) | WO2010068581A1 (enExample) |
| ZA (1) | ZA201103397B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863888B (zh) * | 2004-02-14 | 2012-07-18 | 葛兰素史密斯克莱有限责任公司 | 具有hm74a受体活性的药物 |
| HRP20100725T1 (hr) | 2005-08-10 | 2011-01-31 | Glaxosmithkline Llc | Derivati ksantina kao selektivni agonisti hm74a |
| JP2015510947A (ja) * | 2012-03-22 | 2015-04-13 | トランステック・ファーマ，エルエルシー | 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用 |
| AU2024229006A1 (en) | 2023-02-27 | 2025-09-18 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657327A (en) * | 1970-06-01 | 1972-04-18 | Upjohn Co | Prostaglandin salts of tris(hydroxymethyl)aminomethane |
| US4647585A (en) | 1984-11-08 | 1987-03-03 | E. R. Squibb & Sons, Inc. | Bicycloheptane substituted ethers |
| JP2003534238A (ja) * | 1999-12-15 | 2003-11-18 | スミスクライン・ビーチャム・コーポレイション | シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。 |
| US20030013905A1 (en) | 2002-06-10 | 2003-01-16 | Huang Guishu Kris | Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid |
| CN101863888B (zh) * | 2004-02-14 | 2012-07-18 | 葛兰素史密斯克莱有限责任公司 | 具有hm74a受体活性的药物 |
| GB0423568D0 (en) * | 2004-10-22 | 2004-11-24 | Smithkline Beecham Corp | Novel compounds |
| US20090209561A1 (en) | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| HRP20100725T1 (hr) | 2005-08-10 | 2011-01-31 | Glaxosmithkline Llc | Derivati ksantina kao selektivni agonisti hm74a |
| GB0516464D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
-
2009
- 2009-12-07 ES ES09832421.3T patent/ES2527354T3/es active Active
- 2009-12-07 CA CA2746316A patent/CA2746316C/en not_active Expired - Fee Related
- 2009-12-07 EP EP09832421.3A patent/EP2370440B1/en active Active
- 2009-12-07 JP JP2011539772A patent/JP5666464B2/ja not_active Expired - Fee Related
- 2009-12-07 WO PCT/US2009/066941 patent/WO2010068581A1/en not_active Ceased
- 2009-12-07 MX MX2011006022A patent/MX2011006022A/es active IP Right Grant
- 2009-12-07 BR BRPI0922134-4A patent/BRPI0922134A2/pt not_active Application Discontinuation
- 2009-12-07 US US13/133,486 patent/US9163024B2/en not_active Expired - Fee Related
- 2009-12-07 EA EA201170783A patent/EA020037B1/ru not_active IP Right Cessation
- 2009-12-07 RS RS20150086A patent/RS53777B1/sr unknown
- 2009-12-07 PT PT98324213T patent/PT2370440E/pt unknown
- 2009-12-07 HR HRP20150026AT patent/HRP20150026T1/hr unknown
- 2009-12-07 PL PL09832421T patent/PL2370440T3/pl unknown
- 2009-12-07 DK DK09832421.3T patent/DK2370440T3/en active
- 2009-12-07 SI SI200931113T patent/SI2370440T1/sl unknown
- 2009-12-07 CN CN200980148973.7A patent/CN102245606B/zh not_active Expired - Fee Related
- 2009-12-07 KR KR1020117012975A patent/KR101743783B1/ko not_active Expired - Fee Related
- 2009-12-07 AU AU2009324811A patent/AU2009324811B2/en not_active Ceased
-
2011
- 2011-05-10 ZA ZA2011/03397A patent/ZA201103397B/en unknown
- 2011-05-19 IL IL213032A patent/IL213032A/en not_active IP Right Cessation
-
2014
- 2014-12-16 CY CY20141101047T patent/CY1116032T1/el unknown
-
2015
- 2015-01-16 SM SM201500012T patent/SMT201500012B/xx unknown
- 2015-08-31 US US14/840,549 patent/US20150366870A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/289,996 patent/US20170027945A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2370440B1 (en) | 2014-11-12 |
| AU2009324811A1 (en) | 2011-06-23 |
| AU2009324811B2 (en) | 2013-01-24 |
| US20170027945A1 (en) | 2017-02-02 |
| SMT201500012B (it) | 2015-05-03 |
| HRP20150026T1 (hr) | 2015-02-13 |
| JP5666464B2 (ja) | 2015-02-12 |
| BRPI0922134A2 (pt) | 2015-08-18 |
| WO2010068581A1 (en) | 2010-06-17 |
| CA2746316C (en) | 2017-01-03 |
| US20150366870A1 (en) | 2015-12-24 |
| SI2370440T1 (sl) | 2015-02-27 |
| MX2011006022A (es) | 2011-06-28 |
| PT2370440E (pt) | 2015-01-14 |
| KR20110097816A (ko) | 2011-08-31 |
| ES2527354T3 (es) | 2015-01-22 |
| IL213032A (en) | 2015-02-26 |
| EA020037B1 (ru) | 2014-08-29 |
| CA2746316A1 (en) | 2010-06-17 |
| CY1116032T1 (el) | 2017-01-25 |
| RS53777B1 (sr) | 2015-06-30 |
| EP2370440A1 (en) | 2011-10-05 |
| CN102245606A (zh) | 2011-11-16 |
| IL213032A0 (en) | 2011-07-31 |
| US9163024B2 (en) | 2015-10-20 |
| JP2012511028A (ja) | 2012-05-17 |
| KR101743783B1 (ko) | 2017-06-05 |
| EA201170783A1 (ru) | 2011-12-30 |
| DK2370440T3 (en) | 2014-12-08 |
| EP2370440A4 (en) | 2012-05-30 |
| PL2370440T3 (pl) | 2015-05-29 |
| CN102245606B (zh) | 2014-08-20 |
| US20110251218A1 (en) | 2011-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0823467D0 (en) | Novel Compounds | |
| GB0806536D0 (en) | Novel compounds | |
| GB0800035D0 (en) | Compounds | |
| GB0813142D0 (en) | Novel compounds | |
| GB0808747D0 (en) | Novel compounds | |
| GB0811587D0 (en) | Novel Compounds | |
| IL212799A0 (en) | Novel compounds | |
| GB0812849D0 (en) | Novel compounds | |
| GB0804592D0 (en) | Novel compounds | |
| GB0810981D0 (en) | Novel compounds | |
| GB0810228D0 (en) | Novel compounds | |
| IL213032A0 (en) | Novel compounds | |
| GB0813144D0 (en) | Novel compounds | |
| GB0808030D0 (en) | Novel compounds | |
| GB0804326D0 (en) | Novel compounds | |
| GB0800411D0 (en) | Novel compounds | |
| GB0809479D0 (en) | Novel compounds | |
| GB0807498D0 (en) | Novel compounds | |
| GB0805047D0 (en) | Novel compounds | |
| GB0809478D0 (en) | Novel compounds | |
| GB0810229D0 (en) | Novel compounds | |
| GB0810313D0 (en) | Novel compounds | |
| GB0800839D0 (en) | Novel compounds | |
| GB0807497D0 (en) | Novel compounds | |
| GB0807050D0 (en) | Novel compounds |